PRF vs PRP Composition: How Each Is Prepared
What is the difference between PRF and PRP in composition and how they are made?
Both products start in the same vial of your own blood, and they split apart at the very first decision: whether the tube holds an anticoagulant or nothing at all. Everything downstream, the spin speed, whether you finish with a liquid or a rubbery clot, how fast the growth factors come out, follows from that one choice. If you're weighing the two, you're really comparing two processing routes, not two different drugs.
| Criteria | Plasma concentrate (PRP) | Fibrin matrix (PRF) |
|---|---|---|
| Tube chemistry | Citrate anticoagulant | Plain glass or silica, no additive |
| Spin protocol | One or two spins, up to about 2,000 g | One gentle spin, roughly 60 to 700 g |
| Final form | Injectable liquid, 2x to 7x baseline platelets | Solid elastic clot, membrane or plug |
| Payload release | Bolus, mostly inside the first hour | Gradual, over 7 to 14 days |
Plasma concentrate is drawn into an anticoagulated tube and spun in up to two stages at forces reaching roughly 2,000 g to yield an injectable liquid at two to seven times baseline platelet count, while fibrin is drawn into an additive-free tube and spun once at roughly 60 to 700 g so it clots during the spin into a solid matrix that elutes growth factors over seven to fourteen days.
Why does the use or omission of an anticoagulant change what ends up in the final product?
Most people treat the tube as packaging. It's actually the switch that decides whether you get a liquid you can work on at your own pace or a clot you have to race. Citrate grabs the free calcium your clotting cascade needs at several points, and without that calcium nothing downstream can fire.
Citrate chelates ionized calcium and stops the cascade before thrombin can convert fibrinogen, so a citrated draw stays liquid through repeated spins and needs an added activator to degranulate, while an additive-free glass tube activates factor XII on contact and begins polymerizing within seconds.
How do centrifugation speed and spin duration determine which blood fractions are captured?
Spinning blood is nothing more than sorting by density under an artificial gravity field, and what sets the boundaries is relative centrifugal force, not the rpm number on the dial. Two machines running an identical 3,000 rpm can deliver very different forces because rotor radius differs, which is one of the quieter reasons a published protocol won't reproduce in your room.
Published plasma protocols spread from roughly 10 g to 650 g on the first spin and from under 100 g to about 2,000 g on the second, while fibrin protocols use a single spin near 60 to 700 g, and dropping from roughly 700 g toward 200 g redistributes platelets, leukocytes and monocytes more evenly through the body of the clot.
What cellular composition and platelet concentration distinguish the two preparations?
Concentration is where the label on the box and the count under the microscope drift furthest apart. A liquid concentrate can be counted straight out of the syringe, but a fibrin clot has to be digested before anyone can count what's trapped inside it, which is why the recovery figures you hear quoted for it are softer than they sound.
- Plasma concentration factor: Two to seven times baseline, with four to six times the common working target.
- Fibrin platelet capture: Around 84 percent overall, above 90 percent when the red base is small.
- Leukocyte handling: Plasma is split rich or poor on purpose; fibrin carries them by default.
- Patient ceiling: Thrombocytopenia, anemia, dehydration, or antiplatelet drugs cap what any protocol can yield.
Two-stage plasma protocols commonly land between two and seven times baseline platelet count, while direct counting of digested fibrin clots recovered about eighty-four percent of the drawn platelets overall, rising above ninety percent when the red thrombus at the base was small and falling to roughly two thirds when it was large.
How does the fibrin scaffold form, and what does it change about how the product behaves?
The chemistry itself isn't the interesting part. What changes the product is how fast the fibrin goes down: hit it with added thrombin at high concentration and you get thick, tightly packed bundles that are stiff and resorb fast, let it happen at physiological thrombin levels over several minutes and you get a fine, springy, open-pore network instead. That second version behaves like the provisional matrix your body builds on its own, and it's the entire reason the clot is worth handling.
- Contact activation: Blood meets the charged tube wall and factor XII fires within seconds.
- Thrombin generation: The intrinsic pathway runs at its own pace while the tube is already spinning.
- Fibrin assembly: Monomers self-assemble into a branched polymer with equilateral junctions and open porosity.
- Cross-linking: Factor XIII stabilizes the gel into a clot you can lift out of the tube intact.
- Shaping: Compress it into a membrane, cut plugs for a socket, mince it into a sticky composite, or draw the low-speed liquid version and inject before it sets.
A naturally polymerized fibrin matrix forms a fine, flexible, open-pore network that holds its cargo at the treatment site and is typically remodeled and resorbed over roughly two to three weeks, giving migrating cells a physical substrate for that whole period.
How does growth factor release differ between a liquid concentrate and a clotted matrix?
The cargo is the same in both products: platelet-derived growth factor, transforming growth factor beta, vascular endothelial growth factor, and the rest of the alpha granule cast. What differs is the delivery schedule, and that's the part the tissue actually experiences. Whether you want a jolt or a drip depends on what's in front of you, and that question is still genuinely contested.
| Release behavior | Activated liquid concentrate | Fibrin matrix |
|---|---|---|
| Onset | Near-immediate once calcium or thrombin is added | Begins during polymerization in the tube |
| Bulk of payload | First 10 to 60 minutes | Spread across roughly 7 to 14 days |
| Retention | Free in plasma, cleared by diffusion | Bound to fibrin fibers, released as the scaffold resorbs |
| Better suited to | An acute injection into a joint or a scalp | Soft tissue healing over a graft site |
An activated liquid concentrate releases the majority of its measurable growth factor payload within the first ten to sixty minutes, while a fibrin matrix binds those factors to its fibers and continues measurable elution across roughly seven to fourteen days as the scaffold is resorbed.
How are platelet concentrates classified, and what role does leukocyte content play in those categories?
The acronym on a treatment plan carries almost no information about what the patient actually received. Formal classification systems exist because the naming got out of hand, and they sort products on the two axes that genuinely change the biology: liquid or fibrin matrix, and leukocytes in or out.
- Leukocyte-poor plasma: Liquid concentrate with the buffy coat discarded, for inflammation-sensitive tissue.
- Leukocyte-rich plasma: Liquid concentrate keeping neutrophils, their proteases, and their antimicrobial contribution.
- Leukocyte-poor fibrin: Solid matrix prepared to leave the white cell layer behind.
- Leukocyte-rich fibrin: Solid matrix carrying leukocytes by default, monocyte retention rising as spin force drops.
Platelet concentrates sort into four families along two axes, liquid versus fibrin matrix and leukocyte-rich versus leukocyte-poor, and later systems add quantitative descriptors including absolute platelet count delivered, concentration factor over baseline, red cell content, and whether exogenous activation was used.
What equipment, tube chemistry, and chairside workflow does each preparation require?
In the treatment room the difference shows up as money and minutes. A plasma workflow buys you flexibility and charges you in open handling steps, extra consumables, and twenty-odd minutes of chair time. A fibrin workflow costs about what plain blood tubes cost, but it puts you on a clock you can't negotiate with, and rotor design matters more than most operators assume since a fixed-angle and a swing-out rotor give different clot architecture at the same nominal g-force.
| Requirement | Plasma workflow | Fibrin workflow |
|---|---|---|
| Tubes | Anticoagulated tubes or a proprietary separation device | Plain glass or silica coated, no additive |
| Draw volume | Roughly 15 to 60 mL depending on product needed | A standard tube set |
| Spins | Two, at the higher forces the protocol specifies | One, 3 to 14 minutes at low force |
| Extra kit | Transfer syringes, pipettes, calcium chloride activator | Compression box or plate if membranes are wanted |
| Timing pressure | 15 to 30 minutes total, tolerant of pauses | Tube into the centrifuge inside about a minute |
A plasma workflow needs anticoagulated tubes, a fifteen to sixty millilitre draw, two spins, transfer pipetting, and an activator across roughly fifteen to thirty minutes, while a fibrin workflow needs only additive-free tubes and a single spin of three to fourteen minutes but demands the tube reach the centrifuge within about a minute of the draw.
Which preparation variables most often cause a batch to fail or vary from patient to patient?
The batches that come out wrong were rarely sabotaged by biology. They were lost to the clock, to a rough needle, or to a centrifuge nobody has checked in years. That last one should worry you most, because it hands you a product that looks perfectly acceptable while the force it actually delivered was never what your protocol assumed.
- Draw-to-spin delay: Every extra thirty seconds buys you a shorter, poorly organized, sometimes fragmented clot.
- Traumatic venipuncture: Platelets degranulate in the needle and line, and tissue factor starts clotting early.
- Patient baseline: Platelet count, hematocrit, hydration, recent aspirin, and smoking all cap the yield.
- Temperature and calibration: Cold tubes slow polymerization, a warm room speeds it, and an uncalibrated rotor drifts silently.
The hardest failure to catch is an uncalibrated or mismatched centrifuge, because the delivered g-force differs from the protocol's assumption and the composition drifts quietly and consistently while the finished product still looks acceptable on inspection.
